Cargando…
Prognostic impact of Dynamin related protein 1 (Drp1) in epithelial ovarian cancer
BACKGROUND: The mitochondrial fission protein, Dynamin related protein 1 (Drp1), and its upstream protein calcium/calmodulin–dependent protein kinase I (CaMKI) play a critical role in chemoresistance in ovarian cancer (OVCA). Thus, we examined the expression of Drp1, CaMKI and their phosphorylated f...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7247242/ https://www.ncbi.nlm.nih.gov/pubmed/32448194 http://dx.doi.org/10.1186/s12885-020-06965-4 |
_version_ | 1783538119232978944 |
---|---|
author | Tsuyoshi, Hideaki Orisaka, Makoto Fujita, Yuko Asare-Werehene, Meshach Tsang, Benjamin K. Yoshida, Yoshio |
author_facet | Tsuyoshi, Hideaki Orisaka, Makoto Fujita, Yuko Asare-Werehene, Meshach Tsang, Benjamin K. Yoshida, Yoshio |
author_sort | Tsuyoshi, Hideaki |
collection | PubMed |
description | BACKGROUND: The mitochondrial fission protein, Dynamin related protein 1 (Drp1), and its upstream protein calcium/calmodulin–dependent protein kinase I (CaMKI) play a critical role in chemoresistance in ovarian cancer (OVCA). Thus, we examined the expression of Drp1, CaMKI and their phosphorylated forms and their prognostic impact in epithelial OVCA patients. METHODS: Expression analysis was performed by immunohistochemistry (IHC) of paraffin-embedded tumor samples from 49 patients with epithelial OVCA. Staining intensity and the percentage of positively stained tumor cells were used to calculate an immunoreactive score (IRS) of 0–12. The expression scores calculated were correlated with clinicopathological parameters and patient survival. RESULTS: High immunoreactivity of phospho-Drp1(Ser637) was significantly correlated with high-grade serous carcinoma (HGSC) (p = 0.034), residual postoperative tumor of > 1 cm (p = 0.006), and non-responders to adjuvant chemotherapy (p = 0.007), whereas high expression of CaMKI was significantly correlated with stage III/IV [International Federation of Gynecologists and Obstetricians (FIGO)] (p = 0.011) and platinum-resistant recurrence (p = 0.030). ROC curve analysis showed that Drp1, phospho-Drp1(Ser637) and CaMKI could significantly detect tumor progression with 0.710, 0.779, and 0.686 of area under the curve (AUC), respectively. The Kaplan-Meier survival curve showed that patients with high Drp1, phospho-Drp1(Ser637) and CaMKI levels had significantly poorer progression free survival (PFS) (p = 0.003, p < 0.001 and p = 0.017, respectively). Using multivariate analyses, phospho-Drp1(Ser637) was significantly associated with PFS [p = 0.043, hazard ratio (HR) 3.151, 95% confidence interval (CI) 1.039–9.561]. CONCLUSIONS: Drp1 and CaMKI are novel potential candidates for the detection and prognosis of epithelial OVCA and as such further studies should be performed to exploit their therapeutic significance. |
format | Online Article Text |
id | pubmed-7247242 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-72472422020-06-01 Prognostic impact of Dynamin related protein 1 (Drp1) in epithelial ovarian cancer Tsuyoshi, Hideaki Orisaka, Makoto Fujita, Yuko Asare-Werehene, Meshach Tsang, Benjamin K. Yoshida, Yoshio BMC Cancer Research Article BACKGROUND: The mitochondrial fission protein, Dynamin related protein 1 (Drp1), and its upstream protein calcium/calmodulin–dependent protein kinase I (CaMKI) play a critical role in chemoresistance in ovarian cancer (OVCA). Thus, we examined the expression of Drp1, CaMKI and their phosphorylated forms and their prognostic impact in epithelial OVCA patients. METHODS: Expression analysis was performed by immunohistochemistry (IHC) of paraffin-embedded tumor samples from 49 patients with epithelial OVCA. Staining intensity and the percentage of positively stained tumor cells were used to calculate an immunoreactive score (IRS) of 0–12. The expression scores calculated were correlated with clinicopathological parameters and patient survival. RESULTS: High immunoreactivity of phospho-Drp1(Ser637) was significantly correlated with high-grade serous carcinoma (HGSC) (p = 0.034), residual postoperative tumor of > 1 cm (p = 0.006), and non-responders to adjuvant chemotherapy (p = 0.007), whereas high expression of CaMKI was significantly correlated with stage III/IV [International Federation of Gynecologists and Obstetricians (FIGO)] (p = 0.011) and platinum-resistant recurrence (p = 0.030). ROC curve analysis showed that Drp1, phospho-Drp1(Ser637) and CaMKI could significantly detect tumor progression with 0.710, 0.779, and 0.686 of area under the curve (AUC), respectively. The Kaplan-Meier survival curve showed that patients with high Drp1, phospho-Drp1(Ser637) and CaMKI levels had significantly poorer progression free survival (PFS) (p = 0.003, p < 0.001 and p = 0.017, respectively). Using multivariate analyses, phospho-Drp1(Ser637) was significantly associated with PFS [p = 0.043, hazard ratio (HR) 3.151, 95% confidence interval (CI) 1.039–9.561]. CONCLUSIONS: Drp1 and CaMKI are novel potential candidates for the detection and prognosis of epithelial OVCA and as such further studies should be performed to exploit their therapeutic significance. BioMed Central 2020-05-24 /pmc/articles/PMC7247242/ /pubmed/32448194 http://dx.doi.org/10.1186/s12885-020-06965-4 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Article Tsuyoshi, Hideaki Orisaka, Makoto Fujita, Yuko Asare-Werehene, Meshach Tsang, Benjamin K. Yoshida, Yoshio Prognostic impact of Dynamin related protein 1 (Drp1) in epithelial ovarian cancer |
title | Prognostic impact of Dynamin related protein 1 (Drp1) in epithelial ovarian cancer |
title_full | Prognostic impact of Dynamin related protein 1 (Drp1) in epithelial ovarian cancer |
title_fullStr | Prognostic impact of Dynamin related protein 1 (Drp1) in epithelial ovarian cancer |
title_full_unstemmed | Prognostic impact of Dynamin related protein 1 (Drp1) in epithelial ovarian cancer |
title_short | Prognostic impact of Dynamin related protein 1 (Drp1) in epithelial ovarian cancer |
title_sort | prognostic impact of dynamin related protein 1 (drp1) in epithelial ovarian cancer |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7247242/ https://www.ncbi.nlm.nih.gov/pubmed/32448194 http://dx.doi.org/10.1186/s12885-020-06965-4 |
work_keys_str_mv | AT tsuyoshihideaki prognosticimpactofdynaminrelatedprotein1drp1inepithelialovariancancer AT orisakamakoto prognosticimpactofdynaminrelatedprotein1drp1inepithelialovariancancer AT fujitayuko prognosticimpactofdynaminrelatedprotein1drp1inepithelialovariancancer AT asarewerehenemeshach prognosticimpactofdynaminrelatedprotein1drp1inepithelialovariancancer AT tsangbenjamink prognosticimpactofdynaminrelatedprotein1drp1inepithelialovariancancer AT yoshidayoshio prognosticimpactofdynaminrelatedprotein1drp1inepithelialovariancancer |